US equities |
MU $908.71 ▼-0.59% NVDA $217.07 ▼-1.91% SNDK $1,345.46 ▼-4.12% SPCX $146.05 ▼-4.02% AMD $546.64 ▼-4.24% INTC $93.92 ▼-4.28% AAPL $343.90 ▲+0.27% TSM $418.25 ▼-2.73%
FinancialContent

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.2376 +0.0270 (+12.82%)
Delayed Quote Updated: 12:55 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Key Takeaways From TScan Therapeutics Analyst Ratings ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On TScan Therapeutics ↗
 
Via Benzinga
News headline image
TScan Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Closing of Upsized Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With ↗
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator. 
Via InvestorPlace
News headline image
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗
TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >